SCHEMBL21678782

SCHEMBL21678782

CCCCOC(=O)/C=C/C(=O)OCc1ccccc1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.57
▸ APP P05067 5/20 0.52
▸ HCAR2 Q8TDS4 3/20 0.51
▸ AKR1B10 O60218 2/20 0.50
▸ AKR1B1 P15121 2/20 0.50
▸ TSHR P16473 3/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ MAPT P10636 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ MAPK1 P28482 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ ESR1 P03372 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ NR1H2 P55055 1/20 0.44
▸ RNASEL Q05823 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27952953 0.94 APP (0.54) ATMAPPHCAR2AKR1B10AKR1B1
SCHEMBL27952952 0.94 APP (0.54) ATMAPPHCAR2AKR1B10AKR1B1
SCHEMBL21678750 0.91 APP (0.50) ATMAPPHCAR2AKR1B10AKR1B1
SCHEMBL2340792 0.86 HCAR2 (0.53) HCAR2AKR1B10AKR1B1TSHRLMNA
SCHEMBL78103 0.86 HCAR2 (0.53) HCAR2AKR1B10AKR1B1TSHRLMNA
SCHEMBL21678700 0.85 MAPT (0.52) HCAR2AKR1B10AKR1B1MAPTLMNA
SCHEMBL21678773 0.82 AKR1B1 (0.47) APPHCAR2AKR1B10AKR1B1MAPT
SCHEMBL3445675 0.81 HCAR2 (0.66) ATMAPPHCAR2AKR1B10AKR1B1
SCHEMBL3445677 0.81 HCAR2 (0.66) ATMAPPHCAR2AKR1B10AKR1B1
SCHEMBL5176891 0.80 IDO1 (0.46) HCAR2AKR1B10AKR1B1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866401-B2 Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2024-01-09 — — US disclosed
US-20210179533-A1 SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2021-06-17 — — US disclosed
EP-3611157-A1 SALICYLIC ACID-BASED FUMARATE DERIVATIVE AND USE IN TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES Chongqing Neuropark Bioscience Co., Ltd. (CN) 2020-02-19 — — EP disclosed
US-20200048182-A1 A SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2020-02-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210179533-A1 SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES FH, SUCNR1, SDHB ATM 1675/4885APP 723/4885HCAR2 61/4885
US-20200048182-A1 A SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES FH, SUCNR1, SDHB ATM 1854/4885APP 841/4885HCAR2 75/4885
US-11866401-B2 Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases FH, SUCNR1, SDHB ATM 1671/4885APP 827/4885HCAR2 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback